222 related articles for article (PubMed ID: 11100017)
1. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma.
Hulshof MM; Bouwes Bavinck JN; Bergman W; Masclee AA; Heickendorff L; Breedveld FC; Dijkmans BA
J Am Acad Dermatol; 2000 Dec; 43(6):1017-23. PubMed ID: 11100017
[TBL] [Abstract][Full Text] [Related]
2. Oral calcitriol as a new therapeutic modality for generalized morphea.
Hulshof MM; Pavel S; Breedveld FC; Dijkmans BA; Vermeer BJ
Arch Dermatol; 1994 Oct; 130(10):1290-3. PubMed ID: 7944511
[TBL] [Abstract][Full Text] [Related]
3. Topical calcipotriene for morphea/linear scleroderma.
Cunningham BB; Landells ID; Langman C; Sailer DE; Paller AS
J Am Acad Dermatol; 1998 Aug; 39(2 Pt 1):211-5. PubMed ID: 9704831
[TBL] [Abstract][Full Text] [Related]
4. Morphea and Eosinophilic Fasciitis: An Update.
Mertens JS; Seyger MMB; Thurlings RM; Radstake TRDJ; de Jong EMGJ
Am J Clin Dermatol; 2017 Aug; 18(4):491-512. PubMed ID: 28303481
[TBL] [Abstract][Full Text] [Related]
5. Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3.
Caca-Biljanovska NG; Vlckova-Laskoska MT; Dervendi DV; Pesic NP; Laskoski DS
Adv Exp Med Biol; 1999; 455():299-304. PubMed ID: 10599359
[TBL] [Abstract][Full Text] [Related]
6. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
[TBL] [Abstract][Full Text] [Related]
7. Oral calcitriol as a new therapeutic agent in localized and systemic scleroderma.
Humbert P; Aubin F; Dupond JL; Delaporte E
Arch Dermatol; 1995 Jul; 131(7):850-1. PubMed ID: 7611809
[No Abstract] [Full Text] [Related]
8. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
[TBL] [Abstract][Full Text] [Related]
9. Retinoic acid for treatment of systemic sclerosis and morphea: A literature review.
Thomas RM; Worswick S; Aleshin M
Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 28032675
[TBL] [Abstract][Full Text] [Related]
10. Oral calcitriol: a new therapeutic agent in cutaneous lichen sclerosis.
Ronger S; Viallard AM; Meunier-Mure F; Chouvet B; Balme B; Thomas L
J Drugs Dermatol; 2003 Jan; 2(1):23-8. PubMed ID: 12852377
[TBL] [Abstract][Full Text] [Related]
11. Palindromic morphea: multiple recurrence of morphea lesions in a case of systemic sclerosis.
Mizutani H; Tanaka H; Okada H; Mizutani T; Shimizu M
J Dermatol; 1992 May; 19(5):298-301. PubMed ID: 1644954
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study.
Kroft EB; Groeneveld TJ; Seyger MM; de Jong EM
Am J Clin Dermatol; 2009; 10(3):181-7. PubMed ID: 19354332
[TBL] [Abstract][Full Text] [Related]
13. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma.
Clegg DO; Reading JC; Mayes MD; Seibold JR; Harris C; Wigley FM; Ward JR; Pisko EJ; Weisman MH; Lee P
J Rheumatol; 1994 Jan; 21(1):105-10. PubMed ID: 8151563
[TBL] [Abstract][Full Text] [Related]
14. Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study.
Au K; Mayes MD; Maranian P; Clements PJ; Khanna D; Steen VD; Tashkin D; Roth MD; Elashoff R; Furst DE
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1772-8. PubMed ID: 20740615
[TBL] [Abstract][Full Text] [Related]
15. [Localized scleroderma in children and a therapeutic trial using calcitriol: a therapeutic possibility to define].
Bodemer C; Amoric JC; Hamel-Teillac D; De Prost Y
Ann Dermatol Venereol; 1999 Oct; 126(10):725-6. PubMed ID: 10604016
[No Abstract] [Full Text] [Related]
16. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
17. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
[TBL] [Abstract][Full Text] [Related]
18. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation.
Torres A; García S; Gómez A; González A; Barrios Y; Concepción MT; Hernández D; García JJ; Checa MD; Lorenzo V; Salido E
Kidney Int; 2004 Feb; 65(2):705-12. PubMed ID: 14717945
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.
Seibold JR; Korn JH; Simms R; Clements PJ; Moreland LW; Mayes MD; Furst DE; Rothfield N; Steen V; Weisman M; Collier D; Wigley FM; Merkel PA; Csuka ME; Hsu V; Rocco S; Erikson M; Hannigan J; Harkonen WS; Sanders ME
Ann Intern Med; 2000 Jun; 132(11):871-9. PubMed ID: 10836913
[TBL] [Abstract][Full Text] [Related]
20. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.
Lebwohl M; Menter A; Weiss J; Clark SD; Flores J; Powers J; Balin AK; Kempers S; Glinert RJ; Fleming T; Liu Y; Graeber M; Pariser DM
J Drugs Dermatol; 2007 Apr; 6(4):428-35. PubMed ID: 17668541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
